Impact of thromboprophylaxis across the US acute care setting

Item

http://www.wikidata.org/entity/Q28651190

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Impact of thromboprophylaxis across the US acute care setting

@ast

Impact of thromboprophylaxis across the US acute care setting

@en

Impact of thromboprophylaxis across the US acute care setting

@nl

type

Item

label

Impact of thromboprophylaxis across the US acute care setting

@ast

Impact of thromboprophylaxis across the US acute care setting

@en

Impact of thromboprophylaxis across the US acute care setting

@nl

prefLabel

Impact of thromboprophylaxis across the US acute care setting

@ast

Impact of thromboprophylaxis across the US acute care setting

@en

Impact of thromboprophylaxis across the US acute care setting

@nl

P1476

Impact of thromboprophylaxis across the US acute care setting

@en

P2093

Alexander T Cohen

http://www.w3.org/2001/XMLSchema#string

Frederick A Anderson

http://www.w3.org/2001/XMLSchema#string

Sophie K Rushton-Smith

http://www.w3.org/2001/XMLSchema#string

Wei Huang

http://www.w3.org/2001/XMLSchema#string

P2860

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Predictive power of clinical symptoms in patients with presumptive deep venous thrombosis.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.

Impact of the patient population on the risk for heparin-induced thrombocytopenia.

Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients.

Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient.

Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery.

Economic burden of venous thromboembolism: a systematic review.

P304

e0121429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0121429

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274259200

http://www.w3.org/2001/XMLSchema#string

P698

25816146

http://www.w3.org/2001/XMLSchema#string

P932

4376674

http://www.w3.org/2001/XMLSchema#string